AnisodineCAS# 52646-92-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 52646-92-1 | SDF | Download SDF |
| PubChem ID | 11616712 | Appearance | Powder |
| Formula | C17H21NO5 | M.Wt | 319.36 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-2,3-dihydroxy-2-phenylpropanoate | ||
| SMILES | CN1C2CC(CC1C3C2O3)OC(=O)C(CO)(C4=CC=CC=C4)O | ||
| Standard InChIKey | JEJREKXHLFEVHN-QDXGGTILSA-N | ||
| Standard InChI | InChI=1S/C17H21NO5/c1-18-12-7-11(8-13(18)15-14(12)23-15)22-16(20)17(21,9-19)10-5-3-2-4-6-10/h2-6,11-15,19,21H,7-9H2,1H3/t11?,12-,13+,14-,15+,17-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Anisodine is a traditional anticholinergics. 2. Anisodine can protect optic nerve of primary open angle glaucoma (POAG) through improving the visual function and blood supply of optic nerve. 3. The combination of Anisodine and citicoline with standard steroid and mannitol therapy appears to be effective in the treatment of early optic nerve contusion. 4. Anisodine and anisodamine possess alpha 1-adrenoceptor blocking properties, they are widely used in the People's Republic of China for the management of acute circulatory shock . |
| Targets | Adrenergic Receptor | AChR |
Anisodine Dilution Calculator
Anisodine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1313 mL | 15.6563 mL | 31.3126 mL | 62.6253 mL | 78.2816 mL |
| 5 mM | 0.6263 mL | 3.1313 mL | 6.2625 mL | 12.5251 mL | 15.6563 mL |
| 10 mM | 0.3131 mL | 1.5656 mL | 3.1313 mL | 6.2625 mL | 7.8282 mL |
| 50 mM | 0.0626 mL | 0.3131 mL | 0.6263 mL | 1.2525 mL | 1.5656 mL |
| 100 mM | 0.0313 mL | 0.1566 mL | 0.3131 mL | 0.6263 mL | 0.7828 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Siegeskaurolic acid
Catalog No.:BCN6982
CAS No.:52645-97-3
- Dehydroadynerigenin digitaloside
Catalog No.:BCN4623
CAS No.:52628-62-3
- Huwentoxin IV
Catalog No.:BCC6270
CAS No.:526224-73-7
- Gnetofuran B
Catalog No.:BCN7764
CAS No.:526214-79-9
- Isomorellic acid
Catalog No.:BCN3074
CAS No.:5262-69-1
- Ponicidin
Catalog No.:BCN3231
CAS No.:52617-37-5
- Deacetylasperulosidic acid methyl ester
Catalog No.:BCN1427
CAS No.:52613-28-2
- Epipterosin L
Catalog No.:BCN5680
CAS No.:52611-75-3
- H-Sar-OEt.HCl
Catalog No.:BCC3334
CAS No.:52605-49-9
- Conduritol A
Catalog No.:BCN5683
CAS No.:526-87-4
- D(-)-Tartaric acid
Catalog No.:BCN8460
CAS No.:526-83-0
- Trachelanthamidine
Catalog No.:BCN1991
CAS No.:526-64-7
- Kirenol
Catalog No.:BCN5682
CAS No.:52659-56-0
- A23187, free acid
Catalog No.:BCC6980
CAS No.:52665-69-7
- D-Penylalaninol
Catalog No.:BCC2715
CAS No.:5267-64-1
- Sodium Gluconate
Catalog No.:BCC4721
CAS No.:527-07-1
- Azomycin
Catalog No.:BCC5315
CAS No.:527-73-1
- Herbacetin
Catalog No.:BCN1268
CAS No.:527-95-7
- Ginsenoside Rd
Catalog No.:BCN1074
CAS No.:52705-93-8
- Scillascillin
Catalog No.:BCN5684
CAS No.:52706-07-7
- Isoelemicin
Catalog No.:BCN4760
CAS No.:5273-85-8
- beta-Asarone
Catalog No.:BCN5685
CAS No.:5273-86-9
- Medicarpin 3-O-glucoside
Catalog No.:BCN7773
CAS No.:52766-70-8
- PHA 568487
Catalog No.:BCC7574
CAS No.:527680-57-5
[Therapeutic effect of compound anisodine for primary open angle glaucoma].[Pubmed:22190528]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011 Nov;40(6):659-62.
OBJECTIVE: To evaluate the therapeutic effect of compound Anisodine (CA) for patients with primary open angle glaucoma (POAG). METHODS: According to the modified Hodapp-Parrish-Anderson Visual Fields Grading System, 46 patients with moderate stage POAG were randomized to receive compound Anisodine injection (CA group) or venoruton tablets (control group). Visual acuity (VA), IOP, fundus, visual fields (VF) and the blood flow of optic nerve were observed. RESULTS: The mean of defect (MD) was decreased in CA group after treatment. The PSV and EDV of ophthalmic artery were remarkably improved in both groups, as well as the PSV, EDV and RI of retinal central artery. Compound Anisodine was superior in improving hemodynamics of ophthalmic artery and retinal central artery to venoruton. CONCLUSION: Compound Anisodine can protect optic nerve of POAG through improving the visual function and blood supply of optic nerve.
Efficacy of cytidine-5'-diphosp-bocholine combined with compound anisodine in the treatment of early optic nerve contusion.[Pubmed:22447551]
Eye Sci. 2012 Mar;27(1):37-40.
PURPOSE: To investigate the efficacy of Anisodine combined with cytidine-5'-diphosp-bocholine (citicoline) in the treatment of early optic nerve contusion. METHODS: A total of 33 subjects eligible for inclusion were selected from 105 patients clinically diagnosed with optic nerve contusion. These patients were subsequently divided into the control group (n=16) and the intervention group (n=17). In the control group, the participants received therapy consisting of glucocorticoids, mannitol, vasodilators and vitamin B. The patients in the intervention group additionally received Anisodine in combination with citicoline. The visual acuity was graded on a scale from 0 to 8. RESULTS: Prior to treatment, the 25th, 50th and 75th percentiles of visual acuity grade were 3, 4 and 6.75 for the controls, and 3, 4 and 6.5 for the patients in the intervention group. (P=0.97). After treatment, the 25th, 50th and 75th percentiles of visual acuity grade were 4, 6 and 7.75 in the control group, and 7, 7 and 8 in the intervention group. (P=0.046). A significant difference was observed in both control (P=0.005) and intervention groups (P=0.001) when comparing presenting visual acuity before and after treatment. CONCLUSION: The combination of Anisodine and citicoline with standard steroid and mannitol therapy appears to be effective in the treatment of early optic nerve contusion.
Adrenoceptor blocking properties of atropine-like agents anisodamine and anisodine on brain and cardiovascular tissues of rats.[Pubmed:2879586]
Br J Pharmacol. 1986 Mar;87(3):587-94.
The cholinoceptor antagonists anisodamine and Anisodine are widely used in the People's Republic of China for the management of acute circulatory shock but the mechanism of their beneficial effects is not fully known; we therefore investigated if these agents possessed adrenoceptor blocking properties. The antagonistic effect of anisodamine and Anisodine against the specific binding of the alpha 1-adrenoceptor ligand [3H]-WB-4101 to cardiac and brain tissue membrane preparations and against the effects of phenylephrine on isolated aortic strips and left atria of rats were compared with classical muscarinic receptor and adrenoceptor blocking agents. Both anisodamine and Anisodine possessed alpha 1-adrenoceptor blocking properties; the order of potency of various agents in displacing the binding of [3H]-WB-4101 to receptors and in antagonizing the effects of phenylephrine on aortic strips and left atria was: prazosin greater than atropine greater than anisodamine greater than scopolamine greater than Anisodine. It is concluded that both anisodamine and to a lesser extent Anisodine possess alpha 1-adrenoceptor blocking properties; this antagonistic activity of anisodamine may contribute to its salutary effects on the microcirculation. However, it is unlikely that Anisodine produces a significant adrenoceptor blockade in the clinically used dose-range.
Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats.[Pubmed:24748278]
Eur J Drug Metab Pharmacokinet. 2015 Sep;40(3):245-53.
The compound series of traditional anticholinergics [atropine (Atr), anisodamine (Ani), Anisodine (AT3), and scopolamine (Sco)], naturally occurring belladonna alkaloid, have been approved for numerous therapeutic uses since 1970s. Tiotropium, a novel M receptor antagonist for the treatment of chronic obstructive pulmonary disease, was structurally modified based on atropine-like drugs. Clinical phenomena suggested that the changes of substituent group were related to the pharmacokinetic and pharmacodynamic characteristics of the agents. In an attempt to compare the pharmacokinetics of the series of anticholinergics and investigate the subsets motivating selective anticholinergic potencies, a sensitive LC-MS/MS method was established to analyze the differences of pharmacokinetic parameters. In this paper, we determined the pharmacokinetics of atropine, anisodamine, Anisodine, scopolamine, and tiotropium after i.v. and i.g. single dose administration. After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 +/- 53.66, 267.50 +/- 33.16, 340.50 +/- 44.52, and 483.75 +/- 78.13 ng/mL. Tiotropium had a slightly higher area under the curve with a significant increase of C max value. Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively. Following i.g. administration of tiotropium, the C max value below 20 ng/mL revealed the very low oral absorption. The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %. This work provided relatively comprehensive preclinical data on the series of anticholinergics, which may be used to explain the clinical adverse effects and applications.
